Flagship merges AI biotechs Valo and Montai behind a pipeline led by MTAI-1025

Flagship Pioneering is folding two of its AI drug discovery companies, Valo Health and Montai Therapeutics, into one business that will trade under the Valo brand, the companies said on 11 November¹. Terms were not made public¹.

What the merger brings together

Valo was set up by Flagship in 2020 with almost $100 million of financing to apply AI to drug development in oncology, neurodegenerative and cardiovascular disease¹. Montai followed in 2022 with an initial $50 million¹. The enlarged company's pipeline will be led by two Montai assets: MTAI-1025, an oral NRF2 agonist in phase 1 for ulcerative colitis, and an oral STAT6 inhibitor for atopic dermatitis¹. Montai also brings preclinical and discovery programmes in immunological and respiratory conditions¹.

The partnership books come across intact. Valo signed a Parkinson's disease deal with Germany's Merck KGaA last year worth up to $3 billion, and has agreements with Novo, Pfizer and the contract research organisation Charles River Laboratories¹. Montai worked with Pfizer through Flagship in 2024 on small-molecule candidates for non-small cell lung cancer and has a technology access arrangement with NVIDIA¹.

Brian Alexander, Valo's chief executive and a CEO-partner at Flagship, will run the combined business¹. He said both companies hold that "human evidence should drive drug discovery"¹. Margo Georgiadis, Montai's chief executive and also a Flagship CEO-partner, said the move lets Montai apply its platform "to more targets" across immunology and inflammation and wider therapeutic areas¹.

What it means for the market

The practical effect is that Valo's AI platform, first pitched at cancer, neurodegeneration and heart disease, now sits behind a clinical lead in inflammatory disease. A company that had partnerships but no named clinical lead of its own in this report gains a phase 1 oral asset, while Montai gains a larger partner network and a broader set of targets for its platform¹.

For pharma companies already working with either business, including Merck KGaA, Novo and Pfizer, the companies say the existing agreements will continue¹. Pfizer now deals with a single counterparty where it had two Flagship-linked relationships¹. For investors, the deal shows a venture builder consolidating its own AI portfolio rather than funding two platforms side by side, though without disclosed terms the valuation of either company cannot be judged.

Caveats

The report gives no financial terms, no headcount or cost figures and no timetable for the pipeline¹. MTAI-1025 remains in phase 1, so the combined company's lead has yet to show efficacy data in patients, and the STAT6 inhibitor's stage is not stated¹. The next marker to watch is progress of MTAI-1025 through phase 1 in ulcerative colitis¹.